Gilead reiterated at market perform by JMP

Gilead Sciences Inc. was reiterated at market perform by JMP Securities analyst Adam Cutler. The company's second-quarter earnings per share of $0.56 beat the analyst's estimate of $0.53 and the Street consensus estimate of $0.54. Total revenues of $685 million beat JMP's estimate of $653 million and the Street expectation of $663 million. The analyst increased 2006 product revenue estimates to $2.4 billion from $2.3 billion, with 2006 earnings-per-share estimates increased to $2.20 from $2.15. Shares of the Foster City, Calif.-based biopharmaceutical company were up 36 cents, or 0.61%, at $59.71 on volume of 6,774,323 shares versus the three-month running average of 5,774,323 shares. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.